Breast Cancer

Top Story

Residual cancer burden predicts long-term outcomes across breast cancer subtypes

Residual cancer burden predicts long-term outcomes across breast cancer subtypes
December 13, 2019

Read the Perspective from Adam M. Brufsky, MD, PhD

Meeting NewsPerspective

Menopausal hormone therapy regimens have opposite lasting effects on breast cancer incidence

December 13, 2019
SAN ANTONIO — Two common hormone therapy regimens had opposite long-term effects on breast cancer incidence among postmenopausal women, according to results from…
Meeting NewsPerspective

Accelerated partial breast irradiation effectively prevents recurrence in early breast cancer

December 13, 2019
SAN ANTONIO — Accelerated partial breast irradiation after surgery appeared as effective as whole breast irradiation for preventing recurrence among patients with…
Meeting News

Adjuvant chemotherapy offers limited benefit for invasive lobular carcinoma

December 13, 2019
SAN ANTONIO — Adjuvant chemoendocrine therapy did not extend survival compared with endocrine monotherapy for patients with invasive lobular carcinoma, according…
More Headlines »
CME

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »
Video
Meeting News

VIDEO: More evidence highlights importance of healthy diet for breast cancer survival

June 17, 2019
More »
Resource Centers

CME

Using the Latest Clinical Advances to Guide Your Practice: A Multidisciplinary Tumor Board

This activity is supported by an educational grant from Merck & Co., Inc.

The treatment paradigm for the management of patients with advanced cancer has changed dramatically within recent years…
More »